Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

The missing piece

How AbbVie's Boehringer deal advances its Humira replacement strategy

March 14, 2016 7:00 AM UTC

In preparation for biosimilar competition for Humira adalimumab, AbbVie Inc. is developing a portfolio of products intended to treat the blockbuster's many indications. Last week's deal with Boehringer Ingelheim GmbH added a large missing piece, giving AbbVie a late-stage product in psoriasis that could be the best-in-class anti-IL-23 agent and an advance over IL-17 mAbs.

Humira is approved to treat at least 11 indications across the U.S. and EU and accounted for worldwide net revenues of $14 billion in 2015 - 61% of AbbVie's net revenues that year...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article